An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

375

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Anemia
Interventions
DRUG

Epoetin alfa 3 times weekly /once weekly

Epoetin alfa will be administered as a SC injections at initial dose of 50 IU/kg (3 times weekly for 22 weeks) and at initial dose of 10000 IU (once weekly for 22 weeks)

DRUG

Epoetin alfa once weekly

Epoetin alfa will be administered as a SC injection at initial dose of 10000 IU (once weekly for 44 weeks).

DRUG

Epoetin alfa once every two weeks

Epoetin alfa will be administered as a SC injection at initial dose of 20000 IU (once every 2 weeks for 44 weeks).

Trial Locations (62)

Unknown

Glendale

Tempe

Chula Vista

Long Beach

Los Angeles

Lynwood

Riverside

San Diego

Visalia

Whittier

Yuba City

Colorado Springs

Lakewood

Thornton

Lauderdale Lakes

Miami

Orlando

Palm Beach Gardens

Tampa

West Palm Beach

Zephyrhills

Atlanta

Augusta

Carrollton

Macon

Statesboro

Chicago

Peoria

Baltimore

Bethesda

Methuen

Plymouth

Flint

Hackensack

Old Bridge

Vineland

Albuquerque

Great Neck

New Hartford

New York

Springfield Gardens

Charlotte

Greenville

Maumee

Doylestown

Easton

Erie

Lancaster

Wynnewood

Bamberg

Orangeburg

Sumter

Dyersburg

Arlington

Houston

San Antonio

Chesapeake

Fairfax

Hampton

Richmond

Tacoma

Caguas

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00440557 - An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease | Biotech Hunter | Biotech Hunter